title: Anticancer effect of fucoidan in combination with tyrosine kinase inhibitor lapatinib.
abstract: Background. Despite a number of in vitro and in vivo studies reporting the efficacy of fucoidan in treating various cancers, few studies have measured the efficacy of dietary fucoidan (DF) in combination with cancer drugs. Thus, we examined the sensitivity of DF in combination with the EGFR/ERBB2-targeting reagent lapatinib on cancer cells. Method. We selected six EGFR/ERBB2-amplified cancer cell lines (OE19, NCI-N87, OE33, ESO26, MKN7, and BT474) as an in vitro model and tested their sensitivity to DF alone and to DF in combination with the well-known EGFR/ERBB2-targeting reagent lapatinib. Result. Overall, in drug independent sensitivity test, DF alone did not significantly inhibit the growth of EGFR/ERBB2-amplified cancer cells in vitro. When DF was given in combination with lapatinib, however, it tended to synergistically inhibit cell growth in OE33 but antagonized the action of lapatinib in ESO26, NCI-N87, and OE19. Conclusion. This study suggests that DF has the potential to increase or decrease the effects of certain anticancer drugs on certain cancer cell types. Further study is needed to explore the mechanism of interaction and synergistic antitumor activity of DF in combination with chemotherapy and targeted therapy.
authors.affiliation: Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA ; Sydney Medical School, University of Sydney, Sydney, NSW 2006, Australia.
authors.forename: Byeongsang
authors.identifier: 0000-0001-6063-4548
authors.initials: B
authors.lastname: Oh
authors.affiliation: Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA ; University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
authors.forename: Jihun
authors.identifier: 0000-0003-1469-7307
authors.initials: J
authors.lastname: Kim
authors.affiliation: Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: Weidong
authors.identifier: 0000-0003-2838-6307
authors.initials: W
authors.lastname: Lu
authors.affiliation: Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
authors.forename: David
authors.identifier: 0000-0002-9094-0586
authors.initials: D
authors.lastname: Rosenthal